Phase 1 human clinical trials of two Covid-19 vaccine applicants developed through Bharat Biotech in collaboration with ICMR and Zydus Cadila Ltd have been completed and trials have been moved to Phase 2, ICMR CEO Balram Bhargava said Tuesday.
At a press conference, he said that once an effective vaccine is developed, the concentrate deserves to be in prioritizing and distributing equitably, deploying and logisticing the bloodless chain, storing and educating the other people who administer the vaccine.
There are about 141 applicants being studied internationally and 26 are in other stages of clinical trials, he said.
“Currently, there are 3 vaccines that are in other stages of clinical trials in India. The first is the inactivated virus vaccine developed through Bharat Biotech, which completed its Phase 1 exam at 11 sites and began its Phase 2 exam. Phases 1 and 2 are very early protection and efficacy studies.
“Similarly, Zydus Cadila’s DNA vaccine also finished phase 1 studies at 11 sites and began phase 2 trials that are also progressing. The recombinant Oxford vaccine to be manufactured through the Serum Institute of India, Pune got approval for phase 2 and 3 clinical trials that would start in a week at 17 sites,” Bhargava said at the briefing.
Stressing the urgency of the need for a vaccine, the ICMR official said that while the pandemic is progressing rapidly, the progression of the vaccine takes time “not from a clinical point of view, but also from the social, cultural and regulatory aspects”.
However, he emphasized that until an effective vaccine, a lasting replacement in the behavior, physical estrangement, mask and smart hand hygiene, is probably the most productive vaccine currently available, and even such measures will need to be necessary. surely pursued.
“O item.title”